International News In Brief
This article was originally published in The Gray Sheet
Canada’s MEDEC calls for device strategy
You may also be interested in...
The Supreme Court will take another stab at mapping out a border between patentable and unpatentable diagnostic method claims.
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.